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Abstract
The pathways leading to autoimmunity remain enigmatic despite numerous
lines of experimental inquiry and epidemiological evidence. The mechanisms
leading to the initiation and perpetuation of specific diseases such as primary
biliary cirrhosis (PBC) or multiple sclerosis (MS) remain largely enigmatic,
although it is established that a combination of genetic predisposition and
environmental stimulation is required. The growing number of genome-wide
association studies and the largely incomplete concordance for autoimmune
diseases in monozygotic twins concur to support the role of the environment
(including infectious agents and chemicals) in the breakdown of tolerance leading
to autoimmunity through different mechanisms. In the present article we
illustrate the current hypotheses related to an environmental impact on the
onset of PBC and MS as two representative conditions investigated with
complementary approaches. Indeed, while a role of post-translational antigen
modifications has been proposed for MS, this field remain unexplored in PBC
where, conversely, most evidence is gathered from geoepidemiology and
experimental data on xenobiotics or infectious agents.
Key words: tolerance breakdown, multiple sclerosis, autoantibodies, antigen
modification, glycosilation.
Introduction
The field of autoimmunity currently recognizes a wide variety of
conditions ranging from pure autoimmune to chronic inflammatory
diseases and approximately 100 different entities [1] affecting up to 5%
of the general population in Westernized countries [2]. These prevalence
rates lead to significant economic costs for healthcare systems worldwide
also based on the possible degrees of disability resulting from the multi-
organ involvement and the high comorbidity rate [3-5].
Several common factors are shared by the pathogenetic mechanisms
of different autoimmune disease and manifest as the coined “mosaic of
autoimmunity” to support the multifactorial origin and clinical diversity
[6-8]. Four groups include the major factors contributing to the mosaic:
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i.e. genetics, environment, immune defects, and
hormones [9]. An ideal example to represent the
former two groups is given by the disease
concordance rates in monozygotic compared to
dizygotic twins or other family members [10], as
illustrated in Table I. Somehow surprisingly,
autoimmune disease concordance rates in
monozygotic twins are largely incomplete and are
often based on small series, as in the case of
primary biliary cirrhosis (PBC). Nevertheless, data
support the hypothesis that genetics per se are
insufficient to determine disease onset and that
additional factors, likely related to the environment,
may play a significant role [11]. The present article
will discuss the current views in terms of gene-
environment interplay based on two paradigmatic
examples, i.e. PBC and multiple sclerosis (MS).
Primary biliary cirrhosis is a chronic cholestatic
liver disease characterized by the immune-mediated
destruction of intrahepatic bile ducts resulting in
chronic liver injury and ultimately fibrosis, cirrhosis
and liver failure [12]. The disease recognizes an
autoimmune pathogenesis as well represented by
the specific presence of serum antimitochondrial
antibodies (AMA) and autoreactive T cells [13]. On
the other hand, MS is a chronic inflammatory
neurodegenerative autoimmune disease affecting
the central nervous system [14, 15]. Both conditions
manifest a largely incomplete concordance among
monozygotic twins, 63% in PBC [16] and 30% in MS
[17] despite a significant genetic component 
[18-20]. One interesting feature characterizing both
diseases, similar to autoimmunity per se [8], is
related to the geographical pattern in prevalence
and incidence which also support the envi  -
ronmental influence [4, 7, 21, 22]. These obser  -
vations are now unified into the novel field of
clinical geoepidemiology [6, 23].
Epidemiology and geoepidemiology
Thanks to the globalization and the con  -
sequently easy comparison of data between
different geographical areas the discipline of
geoepidemiology was developed in recent years [6]
to represent the approach by which epidemiological
data across different geographical regions and
populations are compared [4, 8, 24]. It is then
possible to identify genetic, environmental, and
socioeconomical factors involved in the auto  -
immune disease development. On one side it is
possible to determine the contribution of ethno-
genetic factors in development of autoimmune
diseases, analyzing prevalence among different
racial groups sharing the same geographical
locations. On the other hand, it allows to study the
impact of nutrition, light exposure, infections,
xenobiotics and other environmental factors. An
example is given by the evidence that different
diseases share similar geoepidemiological
distributions, as in the cases of type 1 diabetes
mellitus, multiple sclerosis, and inflammatory bowel
disease. These three chronic inflammatory diseases
share the highest prevalence rates in European
Caucasian populations, particularly in Northern
Europe and North America, originally settled by
northern-European people [8] and this observation
suggests common determinants and offers a cue
for future studies, although we cannot overlook the
possible role of disease awareness in different areas.
Of note, a latitudinal gradient was observed for
most autoimmune conditions [4], with highest
prevalence in industrialized countries, especially
Northern Europe and North America, suggesting
a central role played by Westernized lifestyle and
focusing the attention also on other factors such
as sunlight (UV) exposure affecting vitamin D levels,
nutritional habits, and xenobiotics (i.e. chemicals).
Disease MZ concordance rate DZ concordance rate
Primary biliary cirrhosis 0.63 0.00
Primary sclerosing  Concordant pair reported – 
cholangitis
Systemic lupus erithematosus 0.24 0.02
Sjögren’s syndrome Concordant pair reported –
Type I diabetes mellitus 0.21-0.70* 0.00-0.13
Rheumatoid arthritis 12.3-15.4 3.50-3.60
Graves’ disease 0.17-0.29 0.00-0.02
Multiple sclerosis 0.25-0.31* 0.03-4.7
Celiac disease 0.75-0.83 0.11
Table I. Pairwise concordance rates of autoimmune disease in monozygotic and dizygotic twins (n of concordant
sets/n of studied sets) 
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The environmental factors and their
mechanisms in autoimmunity
The search for environmental factors triggering
autoimmunity has led to numerous candidates via
four possible mechanisms [25]. The first
mechanism, molecular mimicry, is perhaps the most
widely investigated mechanism by which infections
may induce autoimmunity. It is characterized by the
cross-reactivity between epitopes (i.e. proteins,
carbohydrates, or DNA sequences) shared by the
pathogen and the host, as well illustrated by
rheumatic fever, a disease often associated with
heart involvement and acute polyarthritis in a large
proportion of cases following streptococcal
infections. In this case streptococcal epitopes (i.e.
N-acetyl-glucosamine and M protein) mimic cardiac
myosin and α-helical proteins present in cardiac
valves, resulting in cardiac damage [26]. Another
classic example is Guillain-Barre ` syndrome (GBS),
an acute polyradiculoneuritis following various
microbial infections or vaccinations. A particular
attention was given to the association between GBS
and Campylobacter jejuni. Antibodies cross-reacting
with both C. jejuni and peripheral nerve gangliosides
are detected in the sera of GBS patients [27] and
recently a significant homology was found between
lipo-oligosaccharides present in C. jejuni and in
ganglioside GM1 [28]. Furthermore, antibodies
directed against the CMV-derived protein UL94 have
been found to cross-react with the cell surface
tetraspanin transmembrane 4 superfamily member
7 (TM4SF7 or NAG-2) molecule inducing apoptosis
of endothelial cells and activation of fibroblasts in
patients with systemic sclerosis [29]. Second,
a polyclonal activation of B-cell occurs when
a lymphotrophic virus infects B cells leading to 
B-cell proliferation causing enhanced antibody
production and the accumulation of circulating
immune complexes that may cause damage to self
tissues [30]. One evocative example is mixed
cryoglobulinemia (MC) induced by hepatitis C virus
(HCV). Mixed cryoglobulinemia is considered the
result of such persistent polyclonal activation [31]
eventually resulting in the appearance of a mixture
of monoclonal and polyclonal autoantibodies that
may result in autoimmunity [31]. The third
mechanism is provided by epitope spreading
occuring when, in an inflammatory state, there is
strong local activation of antigen-presenting cells
(APC). This may result in overprocessing and
overpresentation of antigens, thus priming large
numbers of T cells with broad specificities, possibly
against self antigens [32], as recently described in
translational settings [33, 34]. Fourth and last, the
bystander activation occurs when pro-inflammatory
cytokine production is enhanced after an infection.
An inflammatory microenvironment is created, with
cytokines such as tumor necrosis factor α (TNF-α),
lymphotoxin, nitric oxide (NO), and others, leading
to bystander killing of uninfected cells in the
proximity. Ultimately, this manifests as bystander
activation of autoreactive T cells that were already
present within the self tissue but, due to their prior
low number, were unable to cause an overt
autoimmune disease [35, 36].
Microbial infections
The most widely studied environmental factors
are represented by infectious agents through two
pathways: (i) directly causing the breakdown of
tolerance irrespective of the individual susceptibility;
or (ii) triggering autoimmunity in genetically
susceptible individuals. The issue is largely
enigmatic as most recently supported by solid data
on a hygiene hypothesis [37]. The former pattern
is exemplified by rheumatic fever, in which
antibodies against streptococcal antigens cross-
react with a myocardial antigen causing heart injury
[38] while the latter appears more likely in
autoimmune diseases [39, 40] as exemplified by
Epstein-Barr virus (EBV) infection in systemic lupus
erythematosus (SLE) [41] but also in rheumatoid
arthritis [42], multiple sclerosis [43], Sjögren’s
syndrome [44], autoimmune thyroiditis [45],
autoimmune hepatitis [46], and Kawasaki disease
[47]. Besides EBV, also hepatitis B (HBV) and
cytomegalovirus (CMV) infections have been
associated with autoimmune diseases, as repre  -
sented by the prevalence of serum autoantibodies
in patients with chronic or acute infections. In
particular, relevant titers of antimitochondrial
antibody (AMA), liver kidney microsome (LKM),
antinuclear antibodies (ANA), and smooth muscle
antibodies (SMA) were observed in chronic HBV
infected subjects [48-50]. A potential role for CMV
in the development of SLE has been suggested [51],
similar to inflammatory bowel disease [52],
antiphospholipid syndrome [53] and diabetes
mellitus [54, 55]. Whether these are stochastic
associations or significant pathogenetic links
remains to be elucidated. 
Vaccines
One of the hottest debates in modern medicine
stemmed from the reports of an association
between vaccination and autoimmune diseases,
even though vaccinations protect from infections
and thus may have an indirectly protective role
towards autoimmune diseases. This is well
illustrated by the proposed association between
autism and vaccines [56]. The most studied
associations are GBS after 1976 swine influenza
vaccine, immune thrombocytopenic purpura after
measles, mumps and rubella vaccine, and
myopericarditis after smallpox vaccination [57].
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It has been reported an increased relative risk of
developing autoimmune manifestations in adults
receiving HBV vaccine. The autoimmune mani  -
festations include SLE (OR = 9.1, p < 0.0001, 
95% CI = 2.3-76), rheumatoid arthritis (OR = 18, 
p < 0.0001, 95% CI = 3.1-740), multiple sclerosis 
(OR = 5.2, p < 0.0003, 95% CI = 1.9-20), 
and thrombo  cytopenia (OR = 2.3, p < 0.04, 
95% CI = 1.02-6.2) [58]. The mechanism underlying
the proposed relationship between vaccination and
autoimmune diseases is not clearly understood,
although it is thought to be caused by both vaccine
immunogenic content and adjuvants, which are
used to increase the immune reaction [59].
Nevertheless, we submit that the data supporting
a causative link remain circumstantial [60] and do
not justify a blind refusal of vaccination.
Tobacco
Tobacco smoking has been demonstrated to
alter cytokines release and to exacerbate
autoimmunity modulating pro-inflammatory
cytokines levels (TNF-α, IL-1, IL-6, IL-8, and GM-CSF)
and to decrease anti-inflammatory cytokines levels
(IL-10) [61-63]. The autoimmune diseases associated
with smoking include rheumatoid arthritis, SLE,
Graves’ hyperthyroidism, Crohn’s disease, Good  -
pasture syndrome, thromboangioitis obliterans,
PBC, systemic sclerosis, MS, and fibromyalgia.
Indeed, higher risk and worse prognosis have been
reported in past and current smokers for these
conditions while we should also note that in some
cases tobacco was associated with a reduced risk
of disease, i.e. ulcerative colitis and Behçet’s disease
[9, 64, 65]. One significant link has been proposed
for rheumatoid arthritis. Citrullination, also termed
deimination, is a post-translational modification of
arginine side chains catalyzed by peptidyl arginine
deiminase enzymes with the potential to alter the
structure, antigenicity, and function of proteins. 
In rheumatoid arthritis, antibodies to cyclic
citrullinated peptides are used for diagnosis, though
we argue that the identification of specific
citrullinated antigens, as whole proteins, is awaited.
Four citrullinated antigens, fibrinogen, vimentin,
collagen type II, and α-enolase, have been identified
among others. All four proteins are expressed in
the joint connective tissue and there is evidence
that antibodies to citrullinated fibrinogen and
collagen type II mediate inflammation by the
formation of immune complexes, both in humans
and animal models. Antibodies to citrullinated
proteins are associated with HLA ‘shared epitope’
alleles, and auto  immunity to at least one antigenic
sequence, the CEP-1 peptide from citrullinated 
α-enolase (KIHACitEIFDSCitGNPTVE), demonstrates
a specific association with HLA-DRB1*0401, HLA-
DRB1*0404, 620W PTPN22, and smoking [66]. In
a complementary fashion, a higher expression of
peptidyl arginine deiminase and higher levels of
citrullinated proteins have been observed in the
bronchoalveolar lavage cells of smokers [67].
Nutrition
Numerous systematic studies have confirmed
that nutritional deficiencies can alter the immune
response [68]. In recent years we have witnessed
important advances in “nutritional immunology”
[69], as well represented by the relationship of
vitamins and minerals with autoimmune conditions.
Among these, vitamin D has been demonstrated
to be a modulator of the innate and adaptive
immunity [70] and low levels of vitamin D are
associated with numerous autoimmune diseases
such as multiple sclerosis, SLE, and psoriasis [71,
72]. Accordingly, there is evidence of the beneficial
effects of vitamin D supplementation [73-75]. Other
examples include the lower risk of developing
rheumatoid arthritis with a higher weekly
consumption of fish oil, rich in omega-3 poly  -
unsaturated fatty acids [76], the increased iodine
consumption as a trigger for autoimmune thyroiditis
in genetically susceptible individuals [21], and effects
of low doses of probiotics on disease activity in
inflammatory bowel disease [77]. Most recently, an
association between anti-gluten or anti-gliadin
serum antibodies and autoimmune disease different
from celiac disease, such as MS, was reported [78].
We foresee that clinical and epidemiological studies
focused on the impact of dietary factors on the
geographical gradient of autoimmunity may help
focus on this promising field of research with
potential improvement in patient management [68].
Ultraviolet light
Ultraviolet (UV) light represents an additional
proposed environmental factor capable of
producing direct negative effects in predisposed
individuals. The skin is a barrier against external
agents while hosting both innate immune and
adaptive immune cells and specialized antigen
presenting cells, i.e. Langerhans cell [79]. Of note,
photosensitivity is the most common skin
manifestation in SLE [80]. Cutaneous SLE lesions
often arise in sun-exposed areas and it is well
recognized that sun exposure may also exacerbate
or induce systemic manifestations of this disease
[81] via proposed mechanisms [79]. It has been
demonstrated that human keratinocytes can bind
autoantibodies on their surface following UV
exposure and antibodies against La, Ro, Sm, RNP,
lupus-specific antigens, are specifically associated
to the membrane blebs of cells undergoing
apoptosis after UV damage. The ability of UV light
to induce keratinocyte apoptosis and autoantigen372 Arch Med Sci 3, June / 2011
exposure suggests the role of UV in the lupus
pathogenesis [82]. Conversely, low-dose UV light
can also have immunosuppressive effects, as well
represented by the beneficial effects in psoriasis.
Finally, pre-vitamin D3 is produced from 7-dehydro  -
cholesterol by effect of UV light [79]. 
Xenobiotics
Xenobiotics represent additional etiologic factors
proposed for autoimmune diseases. Xenobiotics
include substances of synthetic, natural, or biologic
origin that may exertan immunosuppressive effect
due to direct toxicity on the immune system cells,
or an immunostimulant effect resulting in
autoimmune manifestations, as well illustrated by
the pseudo-autoimmune conditions triggered by
exposure to chemicals. In 1981 the ingestion of
contaminated rape oil seed resulted in the toxic oil
syndrome with cases of SLE-like disease,
scleroderma-like disease and a number of general
clinical manifestations that persisted in 10% of the
subjects [83]. In the late 1980s in the United States,
the eosinophilic myalgia syndrome was reported
following exposure to L-tryptophan [84]. Since these
earlier reports our knowledge of the links between
chemicals and autoimmune conditions has
considerably grown. As of now silica exposure is
considered a trigger for SLE [85] and scleroderma
[86] while organic solvents such as vinyl chloride
and epoxy resins may also be associated with
scleroderma-like manifestations [87]. Several other
associations have been proposed through three
mechanisms [88-90]. First, a potential direct toxic
effect of xenobiotics may cause cell death by
apoptosis or oncosis, inducing the generation of
immunogenic autoepitopes. Second, chemical
modifications of native cellular proteins by removal
and/or exchange of a hapten has been shown to
change processing in antigen-presenting cells and
may lead to the presentation of cryptic, potentially
immunogenic peptides. Third, xenobiotics may have
the potential to modify host proteins to form
neoantigens. Neoantigen specific T cells and B cells,
once primed, may cross-react with the formerly
inert native autoantigens.
The case of primary biliary cirrhosis
As previously mentioned PBC is a slowly
progressive autoimmune disease in which the loss
of bile ducts leads to decreased bile secretion and
the retention of toxic substances within the liver,
resulting in further hepatic damage, fibrosis,
cirrhosis, and eventually, liver failure. It primarily
affects women. Commonly it develops mainly in the
fifth decade of life and it is uncommon in persons
under 25 years of age [91].
Geoepidemiology
Although PBC is considered a rare disease, recent
data suggest an increasing trend in its incidence
and prevalence, but several factors that make
difficult to study PBC epidemiology have to be
considered. First of all, thus far there are no solid
population-based studies on PBC, due to the rarity
of this condition, and most of the data we have are
descriptive data. Then the accuracy of diagnosis is
difficult to obtain, since it does not exist a perfect
diagnostic marker. Finally, disease awareness in
healthcare providers is raising and may reflect the
increase in prevalence and incidence of PBC cases,
reported in several studies [92]. Based on the
epidemiological data on PBC, it was observed that
there are areas presenting a higher prevalence of
PBC cases. Reported prevalence and incidence rates
of PBC cases are highest in the United Kingdom [93,
94], the scandinavian region [95], and the northern
United States (Table II) [96]. In this case it is difficult
to determine whether this data are due to a true
higher prevalence of cases, possibly influenced by
environmental factors, or to a higher number of
epidemiological studies lead in these areas. Instead,
a lower prevalence and incidence have been
reported in other countries, such as Canada,
Australia, and the Mediterranean countries [97-104].
An interesting population-based study lead in
Australia showed a significant higher PBC
prevalence in Italian, British, and Greek immigrants,
compared to native population [105], an evidence
that may underline the genetic component on the
etiology of PBC or specific environmental priming
occurring early in life. Finally data on PBC
epidemiology are not available in large parts of the
world such as Africa or Asia.
Environmental factors
Based on earlier data on PBC autoantibody
reactivity with xenobiotic-modified autoantigens
[106], Amano et al. [107] studied a large number of
xenobiotics with a structure similar to the lipoic acid
residue on the epitope of PDC-E2, the E2 subunit
of the mitochondrial pyruvate dehydrogenase
complex, that is the main autoreactive antigen
identified so far in PBC [108]. It was observed that
replacement of lipoic acid by certain xenobiotics
enhanced PBC sera reactivity against the PDC-E2
epitope. Particularly, one of the xenobiotics, 
2-nonynoic acid, induced reactivity of PBC sera
stronger than that of the native lipoic acid residue.
Interestingly, the methyl ester of 2-nonynoic acid
has a viol-/peach-like scent and is used as an
ingredient in perfumes. But this is only one of the
several example, the number of exogenous
compounds potentially leading to modifications is
enormous, from food preservatives to home
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detergents to water pollutants [106] and new
mechanisms for haptenization have been recently
described [109]. In addition one such halogenated
compound has been shown to induce AMA
production in rabbits without requiring the peptide
backbone of PDC-E2 [110] but failed to produce liver
lesions. It could reflect the evidence that in humans
AMA titer is detectable several years before the
appearance of liver injury. Finally, xenobiotics are
able to induce epigenetic modifications, as DNA
methylation and histone modifications, that can
lead to gene expression alteration and then
phenotypic changes. These processes may play
a fundamental role in the onset of PBC [111].
Several lines of evidence support the hypothesis
that also some infectious agents are able to be
a trigger in PBC development. In particular it was
suggested by the observation of a significantly
higher rate of urinary tract infections sustained by
Escherichia coli among PBC patients and the
presence of bacterial products in mononuclear cells
surrounding damaged bile ducts [112]. In addition
it has been demonstrated that a history of urinary
tract infections increases the risk of having PBC
[113]. The proposed mechanism to explain this
hypothesis is molecular mimicry, discussed above.
This theory is mostly based on experiments that
demonstrated a cross reactivity between AMA
and/or autoreactive T cells with prokaryotic
antigens of several microbes, including E. coli [114]
which share an ExDK amino acid motif within their
mimicry epitopes.
More recently, Novosphingobium aromatici  -
vorans, an aerobic, free-living Gram-negative
bacterium has been investigated in PBC [115] as
supported by several observations. First, the
bacterium is known to be ubiquitous in the
environment (soil, water), non-pathogenic to
humans and demonstrates the ability to modulate
activation of estrogens [116], which could be linked
to the well-documented female predominance of
PBC. Then it was observed in 100% of anti-PDC-E2
positive and in a fraction of AMA-negative sera
a serum reactivity against two lipoylated proteins
of 47 and 50 KDa from N. aromaticivorans [117].
Titers of antibodies detected against lipoylated
bacterial proteins of N. aromaticivorans were 1000-
fold higher compared to those against E. coli in PBC
patients[117]. Lactobacilli and Chlamydia, which
show some structural homology with the
autoantigen (although reactivity against them is
considerably less than that against either E. coli or
N. aromaticivorans), have also been implicated as
putative pathogens, as well as Helicobacter pylori
and Mycobacterium gordonae [118, 119]. However,
no compelling data have been provided to show
that one individual infectious agent can repro  -
ducibly be detected in patients with PBC. 
In conclusion our current knowledge of the environ  -
mental triggers of PBC includes numerous sus  -
pected agents involved in PBC development, but no
specific agents have been identified as able to be
causative of disease. 
The case of multiple sclerosis
Multiple sclerosis is an inflammatory, demye  -
linating disease of the central nervous system (CNS).
The disease is highly heterogeneous particularly in
its clinical subforms, with an extremely variable
evolution over time. Temporal profile and combination
of neurological findings, appearing as relapses and
Geographical areaY ear Number Incidence Prevalence Gender
of cases (per million) (per million) (M : F)
Europe 1984 569 4 23 1 : 10
Sweden 1985 111 13,3 151 1 : 6
Newcastle, UK 1989 347 19 154 1 : 9
Canada 1990 225 3.26 22 1 : 13
Victoria, Australia 1995 84 – 19 1 : 11
Estonia 1995 69 2.27 26.9 1 : 22
Norway  1998 21 16 146 1 : 9
USA 2000 46 27 402 1 : 8
Newcastle, UK 2001 770 31 251 1 : 10
Victoria,
Australia 2004 249 – 51 1 : 10
Japan 2005 9761 – 78 1 : 9
Canada 2009 227 30 227 1 : 9
Table II. Distribution of prevalence, incidence and sex ratio of primary biliary chirrosis in different countries [7]374 Arch Med Sci 3, June / 2011
remissions, or gradually progressive dysfunctions, led
to classifying MS in clinical subforms coined relapsing-
remitting MS (RRMS), secondary progressive MS
(SPMS), primary progressive MS (PPMS), and pro  -
gressive relapsing MS.
Geoepidemiology
The total number of people affected by MS
worldwide is estimated to be 2-2.5 million, but the
distribution of the disease changes significantly in
different part of the world. Its prevalence varies
between less than 5 cases per 100,000 people in
tropical areas or Asia and more than 100-200 cases
per 100,000 in temperate areas such as the United
States, Canada, New Zealand and parts of Australia
[120, 121]. Furthermore it exists a well-accepted
latitudinal gradient for MS [122]. Highest rates are
recorded in Northern Europe, the British Isles and
Scandinavia, and the areas originally settled from
these locations, which are North America, Australia
and New Zealand [8, 120]. Interestingly it was
observed a lower risk to develop MS in adult
migrants from tropical countries to the UK than
local population, although these differences were
less evident in following generations [123, 124] thus
confirming also the familial risk [19].
There are also important differences in MS
prevalence in different races. Caucasians seems to
be more affected by MS than blacks and Asian
populations, whereas Australian Aboriginals, New
Zealand Maori and North and South-American
Indians have a very low prevalence [121, 125]. After
a large study conducted by WHO it was recently
proposed a socioeconomic gradient, since it has
been observed a higher MS prevalence in Western
Countries, even though it may reflect the availability
of more precise but expensive diagnostic
instruments [126].
Disease pathogenesis and the role 
of post-translational modifications
in creating neo-antigens
Multiple sclerosis pathogenesis remains unclear,
but growing evidence suggests that the disease
could be due to a consequence of multiple genetic,
immunological, and environmental factors [18, 20,
127].
Different hypotheses have been formulated to
explain MS pathology putting into evidence the
heterogeneous and homogeneous features of MS
[128-130]. However, data support the hypothesis
proposed by Lucchinetti et al. [128] of a hetero  -
geneous mechanism of demyelination in which the
following four MS pathological patterns can be
identified: (I) T-cell/macrophage-mediated demye  -
lination, (II) antibody/complement-associated
demyelination, (III) distal oligodendrogliopathy, and
(IV) oligodendrocyte degeneration in the periplaque
white matter. Nevertheless, the difficulty in the
comprehension of MS pathology can be connected
to the presence of post-translational modifications
(PTM) that increase the complexity of myelin
proteins. It is of note that if there are 22 pro  -
teinogenic amino acids (20 of which directly
encoded by the universal genetic code), once
considering PTMs the possible combinations will
become over 400. Moreover, growing evidence
indicates that PTMs (i.e., acetylation, lipidation,
citrullination, glycosylation, etc.), either native or
aberrant, may play a fundamental role for specific
autoantibody recognition in autoimmune diseases
[131].The role of PTMs in MS has not been fully
understood; in fact, it is currently a matter of
debate whether PTMs can have an effective role in
MS pathology and if they can be related to an
autoimmune response [131-133] or a neuro  -
degenerative process [134, 135].These observations
account, at least in part, for the limited results in
the discovery of biomarkers using proteomic
analysis and/or protein microarrays. A number of
autoimmune diseases have been associated with
PTMs, demonstrating that some modifications can
generate new self-antigens or even mask antigens
normally recognized by the immune system in
physiological conditions [131, 136]. It is well accepted
that a number of these chemical modifications
introduced in proteins, during or after their
synthesis, could influence the central and peripheral
tolerance, and subsequent inducing autoimmune
responses to otherwise ignored self-protein [131].
On the other hand, the neurodegenerative
hypothesis is based on metabolic changes in myelin
constituents that altering the PTMs destabilize the
membrane structure leading to myelin degradation
[135]. Once myelin is modified by PTMs some
antigenic fragments could be exposed to the
autoimmune response. Numerous studies indicate
that PTMs, either native or aberrant, may play
a fundamental role in generating neo-epitopes and
thus triggering an autoimmune response,
particularly in MS. For example, rheumatoid arthritis
recognizes anti-citrullinated peptide/protein
autoantibodies in sera of patients because of an
aberrant deimination [137]. In MS, the role of
different PTMs in triggering an autoimmune
response have been investigated considering the
possible mechanisms that could pathologically alter
the PTM profile (e.g. environmental factors and
oxidative stress, pathogens and molecular mimicry).
It was previously reported that Pb metal can
enhance proteins immunogenicity [138] while lead
exposure (PbOAc2) can induce autoantibodies to
nervous system proteins, including MBP [139, 140].
MBP represents 20-30% of total proteins of myelin
sheath and is important for myelin structure [141].
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The putative antigen MBP is widely studied in MS
because it acts as an inter-membrane adhesion
protein enabling myelin structure stability thanks
also to its dynamic pattern of PTMs. MBP binds to
the negatively charged lipids in myelin sheath and
is characterized by different PTMs that differ in their
extent in physiological vs. pathological conditions
[142]. Mice immunized with Pb-altered MBP
developed elevated anti-MBP antibody titer [143]
but a possible correlation with MS disease activity
is far from convincing. Nitric oxide (NO) is involved
in axon and oligodendrocyte degeneration in MS
lesions [144, 145] and increased levels of nitrite have
been detected in cerebrospinal fluid of MS patients
and correlate with clinical activity [146, 147].
Boullerne et al. reported an antibody response
against the uncommon nitrosylated epitope: SNO-
cysteine-BSA, in which BSA was used as a carrier
to expose the modified cysteine [148]. Anti-SNO-
cysteine-BSA IgM antibodies when compared with
healthy controls were detected in: 8/8 (100%) of
RRMS patients in relapse, 6/18 (33%) of clinically
stable RRMS patients, and 16/23 (70%) SPSM
patients. Further, the anti-SNO-cysteine-BSA
antibody titer correlates with disease activity and
increases during clinical activity in MS and was
detected also in sera from Lewis rats with actively
induced MS-like murine disease and it was shown
that anti-SNO-cysteine-BSA antibodies precede anti-
MBP antibodies. The specificity of IgM binding to
SNO-cysteine-BSA was demonstrated by inhibition
experiments at different concentrations. Another
PTM widely studied in MS is glycosylation as it can
affect the immune response and immune tolerance
[131]. Recently, IgM autoantibodies to recombinant
MOG, a putative self-antigen component of normal
myelin of the CNS, have been reported to be
predictors of clinically definite MS after a first
demyelinating event [149, 150]. However, these
results were not confirmed by other studies
probably because differently folded and modified
forms of MOG have been used (Table III) [151, 152].
In fact a recently report demonstrated for the first
time that a solid-phase ELISA based on
a conformationally controlled rMOGED(His)6 on MS
sera and controls failed to detect IgM or IgG
antibodies. Interestingly the rMOGED(His)6 used was
expressed in E. coli after subcloning the cDNA of
the extracellular domain of rat MOG, performing
a refolding procedure on column and affinity
purification. The far-UV Circular Dichroism (CD)
spectra of  rMOGED(His)6 manifested a β-sheet,
Authors MOG type
Berger et al. [149] hMOGED – extracellular, unfolded, and unglycosylated hMOG(28-130)
Gaertner et al. [150] mMOG – full length native, folded, and randomly glycosylated mMOG(1-247)
Mantegazza et al. [151] hMOGED – extracellular, unfolded, and unglycosylated hMOG(29-149)
Lampasona et al. [152] hMOG – full length and unglycosylated hMOG(1-241)
Gori et al. [153] rMOGED – extracellular, folded, and unglycosylated rMOG(1-125)
Table III. Different types of MOG used as antigens for the detection of autoantibodies in multiple sclerosis
Figure 1. Superposition of the 10 optimized structures of hMOG(30-50) (left) and [Asn31(N-β-Glc)]hMOG(30-50) (right)
with the C-terminal part at the bottom showing that the two peptides adopt similar conformations in water/HFA
solution. Autoantibodies detected in a relevant number of MS sera by the MOG glycopeptide and not by the
unglycosylated sequence are directed against the N-linked glucose [155]. Copyright © 2001, American Chemical Society376 Arch Med Sci 3, June / 2011
a characteristic feature of the Ig-fold [153]. MOG 
is a myelin protein presenting a unique N-gly      co  -
sylation site at position 31 (Asn31) and it was
previously reported that N-glucosylation of a MOG
peptide epitope improved the detection of specific
antibodies in MS sera [154]. Moreover, structure-
activity relationship studies demonstrated that the
two MOG derived peptides hMOG(30-50) and the
glycosylated analog [Asn31(N-β-Glc)]hMOG(30-50)
adopt similar conformations in the environment
used for NMR investigations (water/HFA solution).
Thus, the specific antibody-recognition of [Asn31(N-
β-Glc)]hMOG(30-50) is driven by direct interactions
of the antibody binding site with the N-linked
glucose (Figure 1) [155]. Therefore, specifically
glucosylated synthetic peptides, as MS antigenic
probes, have been demonstrated to be powerful
tools for increasing autoantibodies recognition in
MS patients sera, with higher affinity and specificity
compared to recombinant MOG.
Final thoughts on the cases of primary biliary
cirrhosis and multiple sclerosis
The etiology of autoimmune diseases remains
a complex issue that encompasses epidemiology,
clinics, genetics, and experimental data. The
genomic predisposition remains preponderant but
insufficient to explain the different geographic
distribution of these diseases or the incomplete
concordance in MZ twins. Environmental factors are
thus ideal candidates to fill this gap but the
mechanisms remain to be elucidated. Our current
knowledge of the environmental triggers of PBC is
limited to numerous suspected agents involved in
its development, such as xenobiotics or infectious
agents (e.g. E. coli, N. aromaticivorans), but no
specific agents have been identified as able to be
causative of disease and data obtained in animal
models await confirmation. The case of MS, on the
other hand, illustrates a different approach, mostly
based on the PTMs in creating neo-antigens, but
due to the heterogeneity of MS, a clear and rational
association of PTMs with the activity of MS has not
been yet fully elucidated. Geoepidemiology may
provide an important contribution in researching
(looking for) potential environmental factors
involved in autoimmune diseases. Nevertheless, it
remains uncertain whether the latitudinal gradient
observed for most autoimmune conditions reflects
a real different distribution of the disease, possibly
influenced by environmental factors, or it is due to
a greater number of epidemiological studies lead in
certain regions or to the availability of more precise
but expensive diagnostic instruments.
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